April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Use of Clonetics® Human Corneal Epithelial Cell Model for Evaluating Corneal Penetration and Hydrolysis of Ophthalmic Drug Candidates
Author Affiliations & Notes
  • Ashutosh A. Kulkarni
    PPDM, Allergan Inc, Irvine, California
  • William Chang
    PPDM, Allergan Inc, Irvine, California
  • Jie Shen
    PPDM, Allergan Inc, Irvine, California
  • Devin Welty
    PPDM, Allergan Inc, Irvine, California
  • Footnotes
    Commercial Relationships  Ashutosh A. Kulkarni, Allergan Inc (F); William Chang, Allergan Inc (F); Jie Shen, Allergan Inc (F); Devin Welty, Allergan Inc (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3259. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ashutosh A. Kulkarni, William Chang, Jie Shen, Devin Welty; Use of Clonetics® Human Corneal Epithelial Cell Model for Evaluating Corneal Penetration and Hydrolysis of Ophthalmic Drug Candidates. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3259.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The Clonetics® human corneal epithelial cell (cHCEC) culture provides a useful in vitro model for assessing the corneal penetration of ophthalmic drug candidates and to elucidate the effects of formulation on the permeability of drug candidates. We further assessed the utility of this model by generating in vitro-in vivo correlation (IVIVC) for compounds with different chemical templates and with a wide range of corneal permeability values. In addition, we also evaluated the ability of these cells to potentially hydrolyse ester prodrugs.

Methods: : In vitro formulation screening studies were conducted for 5 compounds using the cHCEC model. The cells were monitored for transepithelial electrical resistance (TEER) values before and after treatment to assess integrity of the cell layer throughout the course of the study. The in vitro permeability results were correlated to dose normalized maximal concentrations (Cmax/dose) of the compounds in rabbit aqueous humor following topical administration in vivo. All analytes, including the hydrolysis product (metabolite) of ester prodrugs, were measured by LC-MS/MS.

Results: : All cells used in the permeability studies had pre-treatment TEER ≥ 500 ohm·cm2 confirming the integrity of the cell layer. The apparent in vitro corneal permeability of the 5 compounds ranged from 0.087 X 10-6 - 7.89 X 10-6 cm/s (n=3). The corresponding dose normalized maximal concentration in rabbit aqueous humor (Cmax/dose) exhibited good correlation with the in vitro corneal permeability values (r2 = 0.79). Furthermore, the ester prodrugs were efficiently hydrolysed by cHCEC.

Conclusions: : Good IVIVC for compounds with different chemical templates and a wide range of corneal permeability values and the ability to hydrolyse ester prodrugs further strengthens the utility of cHCEC for in vitro formulation screening of ophthalmic drug candidates.

Keywords: cornea: epithelium • metabolism • anterior chamber 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×